Abstract:Accumulating evidence indicates a critical role for T cells and relevant cytokines in the pathogenesis of systemic lupus erythematosus (SLE). However, the specific contribution of T cells together with the related circulating cytokines in disease pathogenesis and organ involvement is still not clear. In the current study, we investigated relevant molecule expressions and cytokine levels in blood samples from 49 SLE patients and 22 healthy control subjects. The expression of HLA-DR and costimulatory molecules on T cells was evaluated by flow cytometry. Concentrations of serum C-reactive protein, erythrocyte sedimentation rate, anti-double-stranded DNA (anti-dsDNA) antibody, total lgG, complement 3, and complement 4 were measured. Serum cytokines and chemokines were measured by a cytometric bead array assay. Elevated frequencies of HLA-DR+ T cells and ICOS+ T cells were observed in SLE patients with positive anti-dsDNA antibodies compared with those in healthy controls (P < 0.001). The expression of HLA-DR+ T cells was positively correlated with SLEDAI (r = 0.15, P < 0.01). Furthermore, levels of serum IL-6, MCP-1, TNFRI, IL-10, IL-12, and CCL20 were higher in SLE patients compared with healthy controls. In addition, patients with hematologic manifestations displayed elevated frequencies of HLA-DR+ T cells and ICOS+ T cells. Patients with renal manifestations had a decreased frequency of TIGIT+ T cells. These results suggested a dysregulated T cell activity and cytokine expression profiles in SLE subjects. We also developed a chemokine and cytokine profiling strategy to predict the activity of SLE, which has clinical implication for better monitoring the flares and remission during the course of SLE and for assessing therapeutic interventions.

Targeting abnormal lipid metabolism of T cells for systemic lupus erythematosus treatment

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Immunological pathogenesis and treatment of systemic lupus erythematosus

Post-translational Modifications in T Cells in Systemic Erythematosus Lupus

Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus

Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications

Potential therapies targeting metabolic pathways in systemic lupus erythematosus

Dual Effects of Statins Therapy in Systemic Lupus Erythematosus and SLE-related Atherosclerosis: the Potential Role for Regulatory T Cells

T cell metabolism and possible therapeutic targets in systemic lupus erythematosus: a narrative review

Perturbed autophagy intervenes systemic lupus erythematosus by active ingredients of traditional Chinese medicine

Lipidomic And Metabolomic Profiling Reveals Novel Candidate Biomarkers In Active Systemic Lupus Erythematosus

T Cell Metabolism: A New Perspective on Th17/Treg Cell Imbalance in Systemic Lupus Erythematosus

Immunometabolism in the pathogenesis of systemic lupus erythematosus

Promising roles of combined therapy based on immune response and iron metabolism in systemic lupus erythematosus

Abnormal energy metabolism in the pathogenesis of systemic lupus erythematosus

Microbiome and Metabolome Analyses Reveal the Disruption of Lipid Metabolism in Systemic Lupus Erythematosus

Advances in natural products and antibody drugs for SLE: new therapeutic ideas

A cellular overview of immunometabolism in systemic lupus erythematosus

Cell-based therapies for systemic lupus erythematosus.

Review and Progress of Target Drugs in the Treatment of Systemic Lupus Erythematous

Gut Microbiome and Metabolites in Systemic Lupus Erythematosus: Link, Mechanisms and Intervention